TAK-715 Catalog No.:M10952-2 The next generation of epidermal

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

CAS Number: 1245319-54-3

and glutamate efflux in rat cortex and nucleus accumbens

for IFN-γ production of CD62L+ and CD62L− cells

121(4):627-631

TAK-715 Catalog No.:M10952-2 The next generation of epidermalTAK 715 is a potent p38 MAPK inhibitor. which displays potent inhibitory activity (inhibition of p38alpha, IC50 = 7. 1 nM; LPS stimulated release of TNF alpha from THP 1, IC50 = 48 nM; LPS induced TNF alpha production in mice, 87. 6% inhibition at 10 mg kg, po) and no inhibitory activity for major CYPs, including CYP3A4. TAK 715 was selected as a clinical candidate and is now under clinical investigation for the treatment of RA. Product information